The present invention relates to the field of biomarkers. More specifically, the present invention provides methods and compositions useful for diagnosing and/or prognosing prostate cancer. In a specific embodiment, a method for diagnosing prostate cancer or a likelihood thereof in a patient comprising the steps of (a) obtaining a biological sample from the patient (b) subjecting the sample to an assay for detecting expression of one or more of ACSM2A, BDH2, C19orf51, C8orf76, CGB5, CSMD3, DAZ2, DUX4, FAM22G, FAM90A1, GABBR2, GRM3, HMMR, HOXC4, KAAG1, KRIT1, KRTAP20-1, LOC392196, LOC441956, LOC650293, LTB4R, METTL7B, NEK2, OR11H12, OR2J3, OR2L8, OR2M1P, OR2T3, OR4F5, OR52A4, OR5211, PGA3, PHACTR3, PMP2, PRAMEF6, PSG1, SIGLEC10, SOX11, SPDYE1, SSX1, TCEB3B, TCFL5, TFAP2D, TSPY2, UGT2B10, UGT2B11, UGT2B28, WDR49, and WFDC5 and (c) determining that the patient has prostate cancer or a likelihood thereof if the expression of the one or more biomarkers is increased relative to a reference non-prostate cancer sample.
